Cargando…
Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells
Bromodomain (BRD), a protein module that recognizes acetylated lysine residues on histones and other proteins, has recently emerged as a promising therapeutic target for human diseases such as cancer. While most of the studies have been focused on inhibitors against BRDs of the bromo- and extra-term...
Autores principales: | Park, Seul Gi, Lee, Daye, Seo, Hye-Ran, Lee, Shin-Ai, Kwon, Jongbum |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529788/ https://www.ncbi.nlm.nih.gov/pubmed/33004947 http://dx.doi.org/10.1038/s41598-020-73500-7 |
Ejemplares similares
-
BAP1 as a guardian of genome stability: implications in human cancer
por: Kwon, Jongbum, et al.
Publicado: (2023) -
Targeting BAP1 with small compound inhibitor for colon cancer treatment
por: Kang, Minhwa, et al.
Publicado: (2023) -
Functional Health Literacy: Psychometric Properties of the Newest Vital Sign for Portuguese Adolescents (NVS-PTeen)
por: Santos, Osvaldo, et al.
Publicado: (2021) -
Cecr2 mutant mice as a model for human cat eye syndrome
por: Dicipulo, Renée, et al.
Publicado: (2021) -
Mutations in CECR1 associated with a neutrophil signature in peripheral blood
por: Belot, Alexandre, et al.
Publicado: (2014)